J 2015

Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor kappa B (NF-kappa B) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer

BOUCHAL, Pavel, Monika DVOŘÁKOVÁ, Theodoros ROUMELIOTIS, Zbyněk BORTLÍČEK, Ivana IHNATOVÁ et. al.

Basic information

Original name

Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor kappa B (NF-kappa B) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer

Authors

BOUCHAL, Pavel (203 Czech Republic, belonging to the institution), Monika DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution), Theodoros ROUMELIOTIS (300 Greece), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Ivana IHNATOVÁ (703 Slovakia, belonging to the institution), Iva PROCHÁZKOVÁ (203 Czech Republic), JTC HO (826 United Kingdom of Great Britain and Northern Ireland), Josef MARYÁŠ (203 Czech Republic, belonging to the institution), Hana IMRICHOVÁ (203 Czech Republic), Eva BUDINSKÁ (703 Slovakia, belonging to the institution), Rostislav VYZULA (203 Czech Republic), SD GARBIS (300 Greece), Bořivoj VOJTĚŠEK (203 Czech Republic) and Rudolf NENUTIL (203 Czech Republic)

Edition

MOLECULAR & CELLULAR PROTEOMICS, BETHESDA, AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 2015, 1535-9476

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10600 1.6 Biological sciences

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 5.912

RIV identification code

RIV/00216224:14310/15:00080960

Organization unit

Faculty of Science

UT WoS

000357434400007

Keywords in English

Breast cancer; metastasis; low grade; biomarkers; cancer biology; gene expression; iTRAQ; mass spectrometry; Orbitrap FTMS; transcriptomics; Carboxypeptidase B1; NFkB

Tags

Tags

International impact, Reviewed
Změněno: 29/3/2016 15:34, Ing. Andrea Mikešková

Abstract

V originále

Current prognostic factors are insufficient for precise risk-discrimination in breast cancer patients with low grade breast tumors, which, in disagreement with theoretical prognosis, occasionally form early lymph node metastasis. To identify markers for this group of patients, we employed iTRAQ-2DLC-MS/MS proteomics to 24 lymph node positive and 24 lymph node negative grade 1 luminal A primary breast tumors. Another group of 48 high-grade tumors (luminal B, triple negative, Her-2 subtypes) was also analyzed to investigate marker specificity for grade 1 luminal A tumors. From the total of 4405 proteins identified (FDR<5%), the top 65 differentially expressed together with 30 previously identified and control markers were analyzed also at transcript level. Increased levels of carboxypeptidase B1 (CPB1), PDZ and LIM domain protein 2 (PDLIM2), and ring finger protein 25 (RNF25) were associated specifically with lymph node positive grade 1 tumors, whereas stathmin 1 (STMN1) and thymosin beta 10 (TMSB10) associated with aggressive tumor phenotype also in high grade tumors at both protein and transcript level. For CPB1, these differences were also observed by immunohistochemical analysis on tissue microarrays. Upregulation of putative biomarkers in lymph node positive (versus negative) luminal A tumors was validated by gene expression analysis of an independent published data set (n = 343) for CPB1 (p = 0.00155), PDLIM2 (p = 0.02027) and RELA (p = 0.00015). Moreover, statistically significant connections with patient survival were identified in another public data set (n = 1678). Our findings indicate unique pro-metastatic mechanisms in grade 1 tumors that can include up-regulation of CPB1, activation of NF-kappa B pathway and changes in cell survival and cytoskeleton. These putative biomarkers have potential to identify the specific minor subpopulation of breast cancer patients with low grade tumors who are at higher than expected risk of recurrence.

Links

GA14-19250S, research and development project
Name: Nový panel proteinů korelujících se stavem lymfatických uzlin u low-grade nádorů prsu: Klinická verifikace a úloha v invazivitě nádorových buněk
Investor: Czech Science Foundation